A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

Defenders of Medicaid cuts point to the Oregon Health Insurance Experiment to argue that the cuts won’t harm people’s health.

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

Engaging in more than 150 minutes of physical activity per week quadrupled the odds of reversing prediabetes to normal ...

Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated ...

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

LifeSouth blood donors can now discover their risk for diabetes through a unique opportunity. LifeSouth Community Blood ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...